Skip to main
PRME
PRME logo

PRME Stock Forecast & Price Target

PRME Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 43%
Buy 36%
Hold 21%
Sell 0%
Strong Sell 0%

Bulls say

Prime Medicine Inc. is advancing its Prime Editing technology, which holds the potential to address a wide array of diseases with significant unmet medical needs, positioning the company for substantial revenue growth. Projections indicate that the PM577 drug candidate for Wilson's Disease could generate risk-adjusted revenues of $980 million by 2035, reflecting a strong path forward from $32 million in 2030. Furthermore, the promising prospects of ongoing and future programs, particularly in cystic fibrosis and other gene editing applications, suggest a favorable landscape for investor interest and potential technical success in addressing critical health challenges.

Bears say

Prime Medicine Inc. faces significant challenges that may adversely affect its stock outlook, notably the uncertainty surrounding regulatory approvals, which could result in downward revisions of risk-adjusted projections. The company's ability to recruit eligible patients for clinical programs might be hindered, further complicating its path to market. Additionally, high pricing of therapies and safety concerns related to gene editing technologies could undermine market acceptance and present fundamental risks to the overall sector.

PRME has been analyzed by 14 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 36% recommend Buy, 21% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Prime Medicine Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Prime Medicine Inc (PRME) Forecast

Analysts have given PRME a Buy based on their latest research and market trends.

According to 14 analysts, PRME has a Buy consensus rating as of Jul 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Prime Medicine Inc (PRME)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.